Showing results (1-10 of 137) with videos related to
Sort By:
Pageof 14
Tumori|July 23, 2016
Current status of immunotherapy for non-small-cell lung cancerMartina Imbimbo, Giuseppe Lo Russo, Fiona BlackhallTumori|March 17, 2016
Is the chemotherapy era in advanced non-small cell lung cancer really over? Maybe not yetGiuseppe Lo Russo, Martina Imbimbo, Marina Chiara GarassinoTranslational Lung Cancer Research|March 10, 2016
Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?Giuseppe Lo Russo, Claudia Proto, Marina Chiara GarassinoCurrent Opinion in Obstetrics & Gynecology|April 23, 2014
Clinical use of fertility agents and risk of breast cancer: a recent update for an old problemFederica Tomao, Giuseppe Lo Russo, Gian Paolo Spinelli, et al.Critical Reviews in Oncology/Hematology|July 25, 2025
Towards a new approach in pleural mesothelioma: Perioperative immunotherapy and its implicationsPaolo Ambrosini, Alessia Stanzi, Giuseppe Lo Russo, et al.International Review of Cell and Molecular Biology|April 26, 2025
Circulating tumor cells in lung cancer: Integrating stemness and heterogeneity to improve clinical utilityTeresa Beninato, Giuseppe Lo Russo, Rita Leporati, et al.The Oncologist|February 12, 2020
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?Jacob J Adashek, Shumei Kato, Roberto Ferrara, et al.Current Oncology Reports|April 17, 2020
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung CancerGiuseppe Lo Russo, Francesco Facchinetti, Marcello Tiseo, et al.Tumori|February 19, 2020
Recurrent thrombosis followed by Lazarus response in <i>ROS1</i> rearranged NSCLC treated with crizotinib: a case reportTeresa Beninato, Giuseppe Lo Russo, Marina Chiara Garassino, et al.NPJ Precision Oncology|July 2, 2025
Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatmentSilvia Marchesi, Arianna Marinello, Paolo Ambrosini, et al.Pageof 14